Conditions: Liver Transplantation
Keywords: Liver transplantation, mycophenolate, GI problems, Quality of Life
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 34
Healthy volunteers: no

Brief summary:
Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients. This study will assess if a switch from MMF to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI and/or health-related quality of life in liver transplant recipients

Detailed description:

Arms:
arm 1: Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.

Interventions: intervention 1: Enteric-coated Mycophenolate sodium (EC-MPS)
Intervention descriptions: intervention 1: experimental

Protocol document: